Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

A number of other brokerages also recently commented on SUPN. Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective for the company. TD Cowen raised their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. Zacks Research cut Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $48.16 on Friday. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -141.64, a price-to-earnings-growth ratio of 0.52 and a beta of 0.67. The firm’s fifty day moving average price is $48.76 and its 200 day moving average price is $46.10. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The firm’s revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. As a group, analysts expect that Supernus Pharmaceuticals will post 2.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State Street Corp grew its holdings in Supernus Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock valued at $69,614,000 after buying an additional 63,210 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals by 5.5% in the second quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company’s stock valued at $44,121,000 after acquiring an additional 72,991 shares in the last quarter. Woodline Partners LP lifted its position in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after acquiring an additional 338,584 shares during the last quarter. Finally, Sofinnova Investments Inc. increased its position in Supernus Pharmaceuticals by 53.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after purchasing an additional 278,575 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.